Treatment
Mirdametinib clinical trials
We’re tracking 12 recruiting studies that include Mirdametinib, each written for real people, not researchers, below.
Recruiting studies
- NCT05937906RecruitingPhase 1/Phase 2
Chemo and immunotherapy plus short targeted drug for lung cancer
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Dijon, BurgundyAges 18 years+ - NCT06997276RecruitingPhase 1
How the liver affects the drug mirdametinib
This study looks at how mirdametinib is processed in people with liver problems compared to healthy people. It will help doctors understand if the dose needs to be adjusted.
Miami, FloridaAges 18–80 - NCT06666348RecruitingPhase 1/Phase 2
Mirdametinib plus vinblastine for untreated low-grade glioma
This trial tests a combination of two drugs (mirdametinib and vinblastine) for children and young adults with a type of slow-growing brain tumor called low-grade glioma that has certain genetic changes. It may be an option for people who have not received any previous treatment for their tumor.
Calgary, AlbertaAges 2–25 - NCT06693284RecruitingEarly Phase 1
Testing mirdametinib and vorinostat for NF1-related MPNST
This trial tests two targeted drugs, mirdametinib and vorinostat, to see if they can shrink MPNST tumors in people with NF1 before surgery. It is for patients whose tumors lack a specific protein marker (H3K27me3).
Minneapolis, MinnesotaAges 12 years+ - NCT06159166RecruitingPhase 1/Phase 2
Mirdametinib for NF1 skin bumps
This study tests an oral drug called mirdametinib to see if it can shrink skin bumps caused by NF1. If you have at least 24 of these bumps on your skin and are in decent health, you may be able to join.
Baltimore, MarylandAges 18 years+ - NCT04923126RecruitingPhase 1/Phase 2
Mirdametinib for children with low-grade brain tumors
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
Memphis, TennesseeAges 2–24 - NCT06153173RecruitingPhase 2
Mirdametinib for histiocytic disorders
This trial tests a drug called mirdametinib for people with histiocytic disorders, which are rare diseases where certain immune cells grow out of control. It may help shrink tumors and improve symptoms when other treatments haven't worked.
Cincinnati, OhioAges 2 years+ - NCT06843967RecruitingPhase 1/Phase 2
Mirdametinib and palbociclib for liposarcoma
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
Basking Ridge, New JerseyAges 18 years+ - NCT07061951RecruitingPhase 2
Mirdametinib for relapsed or refractory CLL or SLL
This trial tests a drug called mirdametinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if mirdametinib can help shrink the cancer or slow its growth.
Duarte, CaliforniaAges 18 years+ - NCT07237100RecruitingPhase 2
Mirdametinib for advanced NF1-mutant melanoma
This trial tests an experimental oral drug called mirdametinib for people with advanced melanoma that has a specific gene change (NF1 mutation). To join, you must have already had immunotherapy, but not a MEK/ERK/RAF targeted drug before.
San Francisco, CaliforniaAges 18 years+ - NCT07539441RecruitingPhase 1/Phase 2
Mirdametinib for brain and nervous system tumors
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
Basking Ridge, New JerseyAges 18 years+ - NCT05983159RecruitingPhase 2
Targeted therapy for slow-flow or fast-flow vascular malformations
This trial tests two targeted medicines for people with certain types of vascular malformations (abnormal blood vessels). If you have a slow-flow malformation, you may receive alpelisib; if you have a fast-flow malformation, you may receive mirdametinib. Genetic testing is needed to see if your malformation has a specific change that these drugs target.
Parkville, VictoriaAges 2 years+
What Mirdametinib is being studied for
Conditions with recruiting Mirdametinib studies.
Common questions
- Are there clinical trials studying Mirdametinib?
- Yes. Clin2 currently lists 12 recruiting studies that include Mirdametinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Mirdametinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Mirdametinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Mirdametinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.